TL;DR
Get everyday helpers delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A retrospective analysis presented at IDWeek found that most infants in the study no longer had detectable measles-neutralizing antibodies by 6 months, months before the routine first MMR dose at 12 to 15 months. The findings raise questions about protection during infancy, but moving vaccination earlier may reduce vaccine effectiveness and requires further study.
A retrospective analysis presented at the IDWeek annual meeting found that most infants no longer had detectable levels of maternal antibodies that neutralize measles by 6 months of age, leaving a potential protection gap before the routine first MMR dose at 12 to 15 months. The findings do not establish that every infant is unprotected or that vaccination schedules should change, but researchers said they warrant study as measles cases rise in the United States.
Researchers examined blood samples from maternal-infant pairs and adults drawn from the MOMI-Vax and Mix & Match studies, which investigated COVID-19 vaccination. They measured antibodies that bind to measles and antibodies that neutralize the virus. The work was a retrospective analysis, rather than a trial testing a new vaccination schedule.
At birth, infants’ median neutralizing-antibody concentrations against three measles strains exceeded their mothers’ levels. Those concentrations declined, and by 6 months the median was below 120 mIU/mL for all three strains, the study’s correlate of protection. At that age, the shares of infants classified as seropositive were 8.7% for the Edmonston strain, 19.6% for Maryland.USA/18.18 (B3), and 17.4% for Missouri.USA/15.18 (D8).
Lead researcher Buddy Creech, a physician and public health specialist at Vanderbilt University in Nashville, said most six-month antibody readings were near the assays’ lower detection limits, suggesting levels may have been lower still. The analysis also found a difference by mothers’ birth years: infants of mothers born before the 1967 launch of the U.S. measles eradication program were estimated to retain potentially protective antibody for about six months, compared with about four months for infants of mothers born after 1967.
A Possible Gap Before the First Dose
The findings point to a period when some infants may have little measurable antibody protection against measles, while they are still too young for the routine first MMR dose. That concern carries added weight because measles can cause serious complications, and infants are among the groups researchers say should be considered in outbreak response.
However, the study measured antibodies, not the number of infants who went on to contract measles or develop complications. Its results identify a possible vulnerability; they do not show that changing the schedule would prevent infections or improve health outcomes. Any schedule decision would also need to weigh the performance of an early dose against the risks of leaving infants susceptible.
As an affiliate, we earn on qualifying purchases.
Routine MMR Timing and Early Doses
The American Academy of Pediatrics and CDC recommend the first MMR dose at 12 to 15 months and the second at 4 to 6 years. Earlier vaccination is already used for some infants traveling internationally or facing exposure during a local outbreak, but those circumstances differ from changing the routine schedule for all children.
Creech cited a 2019 meta-analysis reporting measles vaccine effectiveness of 51% when the first dose was given at 6 months, compared with 83% at 9 months. The source report said that earlier vaccination may carry trade-offs; the figures do not by themselves establish the best age for routine vaccination. The analysis comes amid a sharp rise in U.S. measles cases: the CDC reported 4,588 cases as of October 22, 2026, compared with 2,289 in all of 2025. The report said 96% of this year’s cases were in people who were unvaccinated or whose vaccination status was unknown.
“What this means is that infants are going to be susceptible to measles virus infection sooner than maybe we previously thought.”
— Buddy Creech, MD, MPH, of Vanderbilt University, speaking at IDWeek
What Antibody Results Cannot Establish
The analysis does not determine how many infants would become infected during the period when antibody levels are low, nor does it test whether a dose at 9 or 10 months would reduce illness. A measured antibody threshold is a correlate of protection, not a direct count of clinical cases. The source report also notes that many six-month results were at the assays’ detection floor, limiting precision about how low levels had fallen.
It is not clear whether the findings apply equally to infants across the country or to all maternal vaccination and infection histories. The samples came from studies initially focused on COVID-19 vaccination, and the source material does not provide the analysis’s sample size or enough detail to assess how representative the participants were. No change to the routine MMR schedule was announced alongside the findings.
Clinical Studies Before Schedule Changes
Creech called for a well-powered clinical study to assess the immune effects of giving an initial dose at 9 or 10 months. Researchers and public health officials will also need to weigh any earlier protection against the lower effectiveness reported for doses given at younger ages, as well as the timing of a second dose.
For now, the routine schedule described by the AAP and CDC remains the first dose at 12 to 15 months and the second at 4 to 6 years. The source report does not identify a pending policy decision or a timeline for new research. Any future recommendation would depend on evidence about both immune response and health outcomes, alongside the changing level of measles circulation.
Key Questions
What did the analysis find?
It found that by 6 months of age, median infant neutralizing-antibody levels were below the study’s 120 mIU/mL correlate of protection for each of three measles strains. The analysis did not measure how many infants became sick.
Does this mean infants have no protection at 6 months?
Not necessarily. The results indicate low or undetectable antibody levels in many infants, but they do not establish that every infant is unprotected. The study’s antibody measure is not the same as a record of infection or illness.
Should parents seek an earlier MMR dose?
The report describes the routine first dose as 12 to 15 months, with earlier doses used in some situations such as international travel or outbreak exposure. It does not announce a schedule change; families should discuss individual vaccination questions with a qualified health professional.
Why not give the first dose at 6 months?
Earlier dosing may offer protection sooner, but the source report cites a 2019 meta-analysis in which vaccine effectiveness was 51% for a first dose at 6 months and 83% at 9 months. Researchers say the effects of earlier routine vaccination need further study.
Has the recommended MMR schedule changed?
No change is reported. The AAP and CDC schedule described in the report remains a first dose at 12 to 15 months and a second dose at 4 to 6 years.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
